The role of genetics and epigenetics in the pathogenesis of systemic sclerosis

Nature Reviews Rheumatology

Volumn 10, Issue 11, 2014, Pages 671-681

  Broen, Jasper C A ^a   Radstake, Timothy R D J ^a   Rossato, Marzia ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CD40 LIGAND; CD70 ANTIGEN; DNA METHYLTRANSFERASE 1; HISTONE DEACETYLASE; HISTONE H3; INTERLEUKIN 4; LET 7A PROTEIN; LET 7G PROTEIN; MICRORNA; MICRORNA 125B; MICRORNA 129 5P; MICRORNA 142 3P; MICRORNA 150; MICRORNA 196A; MICRORNA 206; MICRORNA 21; MICRORNA 29A; MICRORNA 30A; MICRORNA 30B; MICRORNA 92A; PLATELET DERIVED GROWTH FACTOR; SILICON DIOXIDE; STAT4 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TRICHOSTATIN A; UNCLASSIFIED DRUG; HISTONE;

ATG5 GENE; AUTOIMMUNITY; B LYMPHOCYTE; BANK1 GENE; BMPR2 GENE; CD40LG GENE; CD70 GENE; COL1A1 GENE; DIZYGOTIC TWINS; DNA METHYLATION; DNA MODIFICATION; DNASE1L3 GENE; DNMT1 GENE; DRUG EFFECT; EPIGENETICS; FIBROBLAST; FN1 GENE; FOXP3 GENE; GENE EXPRESSION; GENE LOCUS; GENE SILENCING; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE ENVIRONMENT INTERACTION; HDAC GENE; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; IMMUNOLOGICAL TOLERANCE; INCIDENCE; IRAK1 GENE; MONOZYGOTIC TWINS; NLRP1 GENE; PATHOGENESIS; PHENOTYPE; PSORS1C1 GENE; REVIEW; RHOB GENE; SCHIP1 IL12A GENE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC SCLEROSIS; T LYMPHOCYTE; TBX21 GENE; TNFSF4 GENE; TNIP1 GENE; TREH DDX6 GENE; TWIN CONCORDANCE; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETICS; METABOLISM;

DNA METHYLATION; EPIGENESIS, GENETIC; GENETIC PREDISPOSITION TO DISEASE; HISTONES; HUMANS; MICRORNAS; SCLERODERMA, SYSTEMIC;

EID: 84908506366     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2014.128     Document Type: Review

References (101)

1. Varga, J. & Abraham, D. Systemic sclerosis: A prototypic multisystem fibrotic disorder. J. Clin. Invest. 117, 557-567 (2007).
2. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 23, 581-590 (1980).
3. Steen, V. D. Autoantibodies in systemic sclerosis. Semin. Arthritis Rheum. 35, 35-42 (2005).
4. Broen, J. C., Coenen, M. J. & Radstake, T. R. Deciphering the genetic background of systemic sclerosis. Expert Rev. Clin. Immunol. 7, 449-462 (2011).
5. Joseph, C. G. et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 343, 152-157 (2014).
6. McCormic, Z. D., Khuder, S. S., Aryal, B. K., Ames, A. L. & Khuder, S. A. Occupational silica exposure as a risk factor for scleroderma: A meta-analysis. Int. Arch. Occup. Environ. Health 83, 763-769 (2010).
7. Hudson, M. et al. Polyautoimmunity and familial autoimmunity in systemic sclerosis. J. Autoimmun. 31, 156-159 (2008).
8. Englert, H. et al. Familial risk estimation in systemic sclerosis. Aust. N. Z. J. Med. 29, 36-41 (1999).
9. Arora-Singh, R. K. et al. Autoimmune diseases and autoantibodies in the first degree relatives of patients with systemic sclerosis. J. Autoimmun. 35, 52-57 (2010).
10. Arnett, F. C. et al. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum. 44, 1359-1362 (2001).
11. Frech, T. et al. Heritability of vasculopathy, autoimmune disease, and fibrosis in systemic sclerosis: A population-based study. Arthritis Rheum. 62, 2109-2116 (2010).
12. Feghali-Bostwick, C., Medsger, T. A., Jr & Wright, T. M. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum. 48, 1956-1963 (2003).
13. Broen, J. C., Coenen, M. J. & Radstake, T. R. Genetics of systemic sclerosis: An update. Curr. Rheumatol. Rep. 14, 11-21 (2012).
14. Tsuchiya, N. et al. Association of STAT4 polymorphism with systemic sclerosis in a Japanese population. Ann. Rheum. Dis. 68, 1375-1376 (2009).
15. Rueda, B. et al. The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum. Mol. Genet. 18, 2071-2077 (2009).
16. Gourh, P. et al. Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: evidence of possible gene-gene interaction and alterations in TH1/TH2 cytokines. Arthritis Rheum. 60, 3794-3806 (2009).
17. Dieude, P. et al. STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum. 60, 2472-2479 (2009).
18. Avouac, J. et al. Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. Arthritis Rheum. 63, 800-809 (2011).
19. Korman, B. D., Kastner, D. L., Gregersen, P. K. & Remmers, E. F. STAT4: genetics, mechanisms, and implications for autoimmunity. Curr. Allergy Asthma Rep. 8, 398-403 (2008).
20. Redmond, W. L., Ruby, C. E. & Weinberg, A. D. The role of OX40-mediated co-stimulation in T-cell activation and survival. Crit. Rev. Immunol. 29, 187-201 (2009).
21. Bossini-Castillo, L. et al. A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort. Ann. Rheum. Dis. 70, 638-641 (2011).
22. Gourh, P. et al. Association of the C8orf13-BLK region with systemic sclerosis in North-American and European populations. J. Autoimmun. 34, 155-162 (2010).
23. Aliprantis, A. O. et al. Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13. Proc. Natl Acad. Sci. USA 104, 2827-2830 (2007).
24. Lakos, G., Melichian, D., Wu, M. & Varga, J. Increased bleomycin-induced skin fibrosis in mice lacking the TH1-specific transcription factor T-bet. Pathobiology 73, 224-237 (2006).
25. Guarda, G. et al. T cells dampen innate immune responses through inhibition of NLRP1 and NLRP3 inflammasomes. Nature 460, 269-273 (2009).
26. Dieude, P. et al. NLRP1 influences the systemic sclerosis phenotype: A new clue for the contribution of innate immunity in systemic sclerosis-related fibrosing alveolitis pathogenesis. Ann. Rheum. Dis. 70, 668-674 (2011).
27. Orozco, G. et al. Study of the common genetic background for rheumatoid arthritis and systemic lupus erythematosus. Ann. Rheum. Dis. 70, 463-468 (2011).
28. Ito, I. et al. Association of the FAM167A-BLK region with systemic sclerosis. Arthritis Rheum. 62, 890-895 (2010).
29. Dymecki, S. M., Niederhuber, J. E. & Desiderio, S. V. Specific expression of a tyrosine kinase gene, blk, in B lymphoid cells. Science 247, 332-336 (1990).
30. Yokoyama, K. et al. BANK regulates BCR-induced calcium mobilization by promoting tyrosine phosphorylation of IP(3) receptor. EMBO J. 21, 83-92 (2002).
31. Gourh, P. et al. Association of the C8orf13-BLK region with systemic sclerosis in North-American and European populations. J. Autoimmun. 34, 155-162 (2010).
32. Kozyrev, S. V. et al. Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus. Nat. Genet. 40, 211-216 (2008).
33. Orozco, G. et al. Study of functional variants of the BANK1 gene in rheumatoid arthritis. Arthritis Rheum. 60, 372-379 (2009).
34. Dieude, P. et al. BANK1 is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with IRF5 and STAT4. Arthritis Rheum. 60, 3447-3454 (2009).
35. Rueda, B. et al. BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in Caucasians. Ann. Rheum. Dis. 69, 700-705 (2010).
36. Carmona, F. D. et al. New insight on the Xq28 association with systemic sclerosis. Ann. Rheum. Dis. 72, 2032-2038 (2013).
37. Dieudé, P. et al. Evidence of the contribution of the X chromosome to systemic sclerosis susceptibility: Association with the functional IRAK1 196Phe/532Ser haplotype. Arthritis Rheum. 63, 3979-3987 (2011).
38. Zhou, X. et al. HLA-DPB1 and DPB2 are genetic loci for systemic sclerosis: A genome-wide association study in Koreans with replication in North Americans. Arthritis Rheum. 60, 3807-3814 (2009).
39. Radstake, T. R. et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat. Genet. 42, 426-429 (2010).
40. Dieude, P. et al. Independent replication establishes the CD247 gene as a genetic systemic sclerosis susceptibility factor. Ann. Rheum. Dis. 70, 1695-1696 (2011).
41. Allanore, Y. et al. Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. PLoS Genet. 7, e1002091 (2011).
42. Bossini-Castillo, L. et al. Confirmation of TNIP1 but not RHOB and PSORS1C1 as systemic sclerosis risk factors in a large independent replication study. Ann. Rheum. Dis. 72, 602-607 (2013).
43. López-Isac, E. et al. A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility. Arthritis Res. Ther. 16, R6 (2014).
44. Bossini-Castillo, L. et al. A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. Hum. Mol. Genet. 21, 926-933 (2012).
45. Martin, J. E. et al. A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci. Hum. Mol. Genet. 22, 4021-4029 (2013).
46. Mayes, M. D. et al. Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis. Am. J. Hum. Genet. 94, 47-61 (2014).
47. Gorlova, O. et al. Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genet. 7, e1002178 (2011).
48. Katsumoto, T. R., Whitfield, M. L. & Connolly, M. K. The pathogenesis of systemic sclerosis. Annu. Rev. Pathol. 6, 509-537 (2011).
49. Marie, I. et al. Prospective study to evaluate the association between systemic sclerosis and occupational exposure and review of the literature. Autoimmun. Rev. 13, 151-156 (2014).
50. Mora, G. F. Systemic sclerosis: environmental factors. J. Rheumatol. 36, 2383-2396 (2009).
51. Ballestar, E. Epigenetic alterations in autoimmune rheumatic diseases. Nat. Rev. Rheumatol. 7, 263-271 (2011).
52. Meda, F., Folci, M., Baccarelli, A. & Selmi, C. The epigenetics of autoimmunity. Cell Mol. Immunol. 8, 226-236 (2011).
53. Lei, W. et al. Abnormal DNA methylation in CD4+ T cells from patients with systemic lupus erythematosus, systemic sclerosis, and dermatomyositis. Scand. J. Rheumatol. 38, 369-374 (2009).
54. Jiang, H. et al. Demethylation of TNFSF7 contributes to CD70 overexpression in CD4+ T cells from patients with systemic sclerosis. Clin. Immunol. 143, 39-44 (2012).
55. Komura, K. et al. Blockade of CD40/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse. Ann. Rheum. Dis. 67, 867-872 (2008).
56. Lian, X. et al. DNA demethylation of CD40L in CD4+ T cells from women with systemic sclerosis: A possible explanation for female susceptibility. Arthritis Rheum. 64, 2338-2345 (2012).
57. Selmi, C. et al. X chromosome gene methylation in peripheral lymphocytes from monozygotic twins discordant for scleroderma. Clin. Exp. Immunol. 169, 253-262 (2012).
58. Wang, Y. Y. et al. DNA hypermethylation of the Forkhead box protein 3 (FOXP3) promoter in CD4+ T cells of patients with systemic sclerosis. Br. J. Dermatol. http://dx.doi.org/10.1111/bjd.12913.
59. Wang, Y., Fan, P. S. & Kahaleh, B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum. 54, 2271-2279 (2006).
60. Dees, C. et al. The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis. Ann. Rheum. Dis. 73, 1232-1239 (2013).
61. Wang, Y. & Kahaleh, B. Epigenetic repression of bone morphogenetic protein receptor II expression in scleroderma. J. Cell Mol. Med. 17, 1291-1299 (2013).
62. Huber, L. C. et al. Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. Arthritis Rheum. 56, 2755-2764 (2007).
63. Hemmatazad, H. et al. Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis. Arthritis Rheum. 60, 1519-1529 (2009).
64. Ghosh, A. K. et al. p300 is elevated in systemic sclerosis and its expression is positively regulated by TGF-β: epigenetic feed-forward amplification of fibrosis. J. Invest. Dermatol. 133, 1302-1310 (2013).
65. Bhattacharyya, S. et al. Fibroblast expression of the coactivator p300 governs the intensity of profibrotic response to transforming growth factor β. Arthritis Rheum. 52, 1248-1258 (2005).
66. Ghosh, A. K., Yuan, W., Mori, Y. & Varga, J. Smad-dependent stimulation of type I collagen gene expression in human skin fibroblasts by TGF-β involves functional cooperation with p300/CBP transcriptional coactivators. Oncogene 19, 3546-3555 (2000).
67. Bhattacharyya, S. et al. Egr-1 induces a profibrotic injury/repair gene program associated with systemic sclerosis. PLoS ONE 6, e23082 (2011).
68. Kramer, M. et al. Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis. Ann. Rheum. Dis. 72, 614-620 (2013).
69. Wang, Y. et al. Aberrant histone modification in peripheral blood B cells from patients with systemic sclerosis. Clin. Immunol. 149, 46-54 (2013).
70. Li, H. et al. MicroRNA array analysis of microRNAs related to systemic scleroderma. Rheumatol. Int. 32, 307-313 (2012).
71. Zhu, H. et al. MicroRNA expression abnormalities in limited cutaneous scleroderma and diffuse cutaneous scleroderma. J. Clin. Immunol. 32, 514-522 (2012).
72. Honda, N. et al. TGF-β-mediated downregulation of microRNA-196a contributes to the constitutive upregulated type I collagen expression in scleroderma dermal fibroblasts. J. Immunol. 188, 3323-3331 (2012).
73. Honda, N. et al. miR-150 down-regulation contributes to the constitutive type I collagen overexpression in scleroderma dermal fibroblasts via the induction of integrin β3. Am. J. Pathol. 182, 206-216 (2013).
74. Zhu, H. et al. MicroRNA-21 in scleroderma fibrosis and its function in TGF-β-regulated fibrosis-related genes expression. J. Clin. Immunol. 33, 1100-1109 (2013).
75. Vettori, S., Gay, S. & Distler, O. Role of MicroRNAs in fibrosis. Open. Rheumatol. J. 6, 130-139 (2012).
76. Jiang, X., Tsitsiou, E., Herrick, S. E. & Lindsay, M. A. MicroRNAs and the regulation of fibrosis. FEBS J. 277, 2015-2021 (2010).
77. Peng, W. J. et al. MicroRNA-29: A potential therapeutic target for systemic sclerosis. Expert Opin. Ther. Targets. 16, 875-879 (2012).
78. Maurer, B. et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum. 62, 1733-1743 (2010).
79. Bhattacharyya, S. et al. Toll-like receptor 4 signaling augments transforming growth factor-β responses: A novel mechanism for maintaining and amplifying fibrosis in scleroderma. Am. J. Pathol. 182, 192-205 (2013).
80. Makino, K. et al. The downregulation of microRNA let-7a contributes to the excessive expression of type I collagen in systemic and localized scleroderma. J. Immunol. 190, 3905-3915 (2013).
81. Makino, K. et al. Discoidin domain receptor 2-microRNA 196a-mediated negative feedback against excess type I collagen expression is impaired in scleroderma dermal fibroblasts. J. Invest Dermatol. 133, 110-119 (2013).
82. Wang, Z. et al. Detection of hair-microRNAs as the novel potent biomarker: evaluation of the usefulness for the diagnosis of scleroderma. J. Dermatol. Sci. 72, 134-141 (2013).
83. Nakashima, T. et al. Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts. J. Immunol. 188, 3573-3583 (2012).
84. Tanaka, S. et al. Alteration of circulating miRNAs in SSc: miR-30b regulates the expression of PDGF receptor β. Rheumatology (Oxford) 52, 1963-1972 (2013).
85. Yamakage, A., Kikuchi, K., Smith, E. A., LeRoy, E. C. & Trojanowska, M. Selective upregulation of platelet-derived growth factor α receptors by transforming growth factor β in scleroderma fibroblasts. J. Exp. Med. 175, 1227-1234 (1992).
86. Sing, T. et al. microRNA-92a expression in the sera and dermal fibroblasts increases in patients with scleroderma. Rheumatology. (Oxford) 51, 1550-1556 (2012).
87. Kajihara, I. et al. Increased accumulation of extracellular thrombospondin-2 due to low degradation activity stimulates type I collagen expression in scleroderma fibroblasts. Am. J. Pathol. 180, 703-714 (2012).
88. Koba, S. et al. Expression analysis of multiple microRNAs in each patient with scleroderma. Exp. Dermatol. 22, 489-491 (2013).
89. Kawashita, Y. et al. Circulating miR-29a levels in patients with scleroderma spectrum disorder. J. Dermatol. Sci. 61, 67-69 (2011).
90. Makino, K. et al. Circulating miR-142-3p levels in patients with systemic sclerosis. Clin. Exp. Dermatol. 37, 34-39 (2012).
91. Broen, J. C. & Radstake, T. R. How birds of a feather flock together: genetics in autoimmune diseases. Expert Rev. Clin. Immunol. 7, 127-128 (2011).
92. Schaub, M. A., Boyle, A. P., Kundaje, A., Batzoglou, S. & Snyder, M. Linking disease associations with regulatory information in the human genome. Genome Res. 22, 1748-1759 (2012).
93. Maurano, M. T. et al. Systematic localization of common disease-associated variation in regulatory DNA. Science 337, 1190-1195 (2012).
94. Dozmorov, M. G., Wren, J. D. & Alarcón-Riquelme, M. E. Epigenomic elements enriched in the promoters of autoimmunity susceptibility genes. Epigenetics 9, 276-285 (2013).
95. Bell, J. T. et al. DNA methylation patterns associate with genetic and gene expression variation in HapMap cell lines. Genome Biol. 12, R10 (2011).
96. Kasowski, M. et al. Variation in transcription factor binding among humans. Science 328, 232-235 (2010).
97. Saunders, M. A., Liang, H. & Li, W. H. Human polymorphism at microRNAs and microRNA target sites. Proc. Natl Acad. Sci. USA 104, 3300-3305 (2007).
98. Sethupathy, P. & Collins, F. S. MicroRNA target site polymorphisms and human disease. Trends Genet. 24, 489-497 (2008).
99. Li, S. et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat. Immunol. 15, 195-204 (2014).
100. Werner, H. M., Mills, G. B. & Ram, P. T. Cancer systems biology: A peek into the future of patient care? Nat. Rev. Clin. Oncol. 11, 167-176 (2014).
101. Farina, A. et al. Epstein-Barr virus infection induces aberrant TLR activation pathway and fibroblast-myofibroblast conversion in scleroderma. J. Invest. Dermatol. 134, 954-964 (2014).